Description
BSE circular announcing the listing of equity shares of Gaudium IVF and Women Health Limited on the exchange, providing scrip details and trading commencement information.
Summary
BSE has issued a circular announcing the listing of equity shares of Gaudium IVF and Women Health Limited on the Bombay Stock Exchange. This circular provides the scrip code, ISIN, face value, issue price, and trading commencement details for the company’s IPO. Gaudium IVF and Women Health Limited is a healthcare company focused on in-vitro fertilisation (IVF) and women’s health services.
Key Points
- Equity shares of Gaudium IVF and Women Health Limited admitted to dealings on BSE
- Trading to commence on February 26, 2026
- Listed under the SME/Main Board segment of BSE
- Shares available for trading from the date of this circular
- Both BSE (notice #41) and NSE circulars issued on the same date confirming dual-exchange listing
Regulatory Changes
No new regulatory changes introduced. This circular operationalises the IPO listing under existing SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and BSE listing regulations.
Compliance Requirements
- Market participants and brokers may commence trading in Gaudium IVF and Women Health Limited equity shares from the date of listing
- Lock-in provisions as per SEBI ICDR Regulations 2018 apply to promoter and anchor investor shares
- Investors must follow standard settlement procedures (T+1 rolling settlement)
- All trading to be conducted in dematerialised form only
Important Dates
- February 26, 2026: Listing date and commencement of trading on BSE
- Lock-in expiry dates for promoter/anchor shares as specified in the company’s prospectus
Impact Assessment
Market Impact: The listing of Gaudium IVF and Women Health Limited provides market participants access to a healthcare/fertility services company on the public markets. The healthcare sector, particularly IVF services, has seen increasing investor interest in India due to rising demand for fertility treatments.
Investor Considerations: Investors should review the company’s prospectus for full details on lock-in periods, financial performance, and business prospects before trading. The listing provides price discovery and liquidity for the company’s shares.
Sector Context: Gaudium IVF operates in the growing assisted reproductive technology (ART) sector in India, which is experiencing increased demand driven by lifestyle changes and delayed parenthood trends.
Impact Justification
IPO listing circular marking commencement of trading for a newly listed healthcare/IVF company; high importance for investors seeking to trade from listing date